Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

Journal of Nuclear Medicine - China
doi 10.2967/jnumed.111.101865
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society of Nuclear Medicine

Related search

Immuno-Pet Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-In-Human Trial

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma

English

Pretargeted Molecular Imaging and Radioimmunotherapy

Theranostics
MedicineToxicologyPharmaceuticsPharmacology
2012English

Cabozantinib in Progressive Medullary Thyroid Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Association of Medullary Carcinoma of the Thyroid With Carcinoembryonic Antigen

British Journal of Cancer
Cancer ResearchOncology
1976English

Medullary Thyroid Carcinoma

2020English

Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

Urology
Urology
2008English

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy